Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Ambarella surges after report says company exploring strategic options, including sale (SeekingAlpha) +++ AMBARELLA Aktie +15,53%

ATEA Aktie

 >ATEA Aktienkurs 
13 EUR    -0.8%    (Tradegate)
Ask: 13.08 EUR / 240 Stück
Bid: 12.96 EUR / 240 Stück
Tagesumsatz: 134 Stück
Realtime Kurs von 8 bis 22 Uhr!
ATEA Aktie über LYNX handeln
>ATEA Performance
1 Woche: -0,4%
1 Monat: +0,5%
3 Monate: +12,5%
6 Monate: +11,7%
1 Jahr: -7,3%
laufendes Jahr: +10,5%
>ATEA Aktie
Name:  ATEA ASA NK 1
Land:  Norwegen
Sektor:  Dienstleistungen
ISIN/ Wkn:  NO0004822503 / 884578
Symbol/ Ticker:  MKL (Frankfurt)
Kürzel:  FRA:MKL, ETR:MKL, MKL:GR
Index:  -
Webseite:  https://www.atea.com/
Marktkapitalisierung:  1460 Mio. EUR
Umsatz:  30846.57 Mio. EUR
EBITDA:  1267.55 Mio. EUR
Gewinn je Aktie:  0.495 EUR
Schulden:  1944.73 Mio. EUR
Liquide Mittel:  763.13 Mio. EUR
Umsatz-/ Gewinnwachstum:  12.5% / -15.6%
KGV/ KGV lG:  22.48 / 20.58
KUV/ KBV/ PEG:  0.47 / 3.71 / -
Gewinnm./ Eigenkapitalr.:  2.1% / 16.62%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / 4.66%
Div. Historie:  15.11.22 - 0.26518€
27.04.18 - 0.336€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  ATEA
Letzte Datenerhebung:  24.06.25
>ATEA Eigentümer
Aktien: 111.43 Mio. St.
f.h. Aktien: 70.49 Mio. St.
Insider Eigner: 29.25%
Instit. Eigner: 44.53%
Leerverk. Aktien: -
>ATEA Peer Group

 
24.06.25 - 13:03
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America (GlobeNewswire EN)
 
C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada...
18.06.25 - 09:30
Atea Share Savings Program – notification of trade (Cision)
 
Reference is made to the stock exchange notice on June 6, 2023, regarding the Employee Share Savings Program. On June 17, employees received bonus shares after having held shares purchased through the program for the required vesting period. In total, 13,331 shares have been transferred from Atea's treasury holdings to employee accounts. Shares were transferred from Atea's treasury share holdings at a share price of NOK 149.60 per share, corresponding to the volume-weighted average share price on the vesting date June 4, 2025. Following the transaction, Atea holds 879,191 of its...
09.06.25 - 07:01
Atea recognized as one of “Europe′s 50 Most Sustainable Corporations” (Cision)
 
Atea has today been recognized as one of “Europe's 50 Most Sustainable Corporations”. The ranking follows the Corporate Knights 2025 Global 100 methodology, with eligibility extended to STOXX Europe 600 constituents and the top 100 Europe-based publicly traded companies. More information can be found here: Europe 50 Most Sustainable Companies Ranking (https://www.corporateknights.com/resources/europe50-companies-copy/) Contact Information: Robert Giori, CFO, Atea ASA, mobile: +47 934 09 188 Andreas Antonsen, Director of Corporate Responsibility, mobile: +46 722 44 87 84 Nelly...
21.05.25 - 07:01
Ex dividend NOK 3.50 today (Cision)
 
The shares in Atea ASA will be traded ex dividend NOK 3.50 as from today, 21 May 2025. For further information, please contact: Steinar Sønsteby, CEO Atea ASA, mobile (+47) 930 55 655 Robert Giori, CFO Atea ASA, mobile (+47) 934 09 188...
12.05.25 - 23:33
Atea Pharmaceuticals GAAP EPS of -$0.40 beats by $0.01 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.05.25 - 22:12
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire EN)
 
Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV...
08.05.25 - 10:06
Atea Share Savings Program – notification of trade (Cision)
 
Atea employees have purchased shares in Atea ASA according to the terms of the Atea Employee Share Savings Program (the “Program”). The purpose of the Program is to engage employees and foster a culture of employee ownership in the Company. Under the terms of the Program, participating employees may allocate a fixed amount of their monthly after-tax salary to purchase shares in Atea ASA (up to a maximum per month of NOK 1,000 in Norway, SEK 1,000 in Sweden, DKK 700 in Denmark and EUR 100 per month in Finland and the Baltic countries). Shares are purchased by employees from Atea ASA's...
30.04.25 - 17:36
Mandatory notification of trade (Cision)
 
On April 30, the following transactions took place in Atea ASA (the Company): 1. Exercise and conversion of stock options Employees of the Atea Group exercised stock options.  Upon exercise, the stock options are converted into the right to receive ATEA shares of an equivalent intrinsic value.  The intrinsic value is calculated based on the volume weighted average price of the ATEA share on the day preceding the exercise. In total, 443,384 stock options with a weighted average strike price of NOK 121.75 were exercised and converted into the right to receive 65,941 Atea shares, based...
29.04.25 - 07:06
Atea Q1 2025 financial report and presentation (Cision)
 
Atea reported record high operating profit for the first quarter, driven by strong sales growth across all geographies and across all lines of business. Gross sales in Q1 increased by 16.4% to NOK 13.3 billion. Organic growth in constant currency was 13.9%. Currency fluctuations had a positive impact of 2.2% on sales growth. Hardware sales grew by 16.2%, software sales grew by 21.4%, and services sales grew by 8.6% from last year. Total revenue (IFRS) grew by 12.5% to NOK 8.6 billion. Gross profit grew by 5.0% to NOK 2.7 billion, as margins fell due to an increased proportion of...
25.04.25 - 07:00
Atea Listed Among Europe′s Climate Leaders 2025 (Cision)
 
(OSLO, NORWAY) Atea is honored to announce its inclusion in the 2025 Europe's Climate Leaders list, published by the Financial Times in collaboration with Statista. This marks the fourth time that Atea has been recognized for its progress in reducing greenhouse gas emissions intensity, and the third consecutive recognition since the rating started in 2021. The 2025 Europe's Climate Leaders list evaluates companies based on their Scope 1 and 2 emissions intensity, which measures emissions relative to revenue, from 2018 to 2023. The list also considers transparency and performance in Scope...
23.04.25 - 13:03
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 (GlobeNewswire EN)
 
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the full results from the Phase 2 clinical study of Atea's regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV) infection will be presented at the European Association for the Study of the Liver (EASL) Congress 2025. In addition, pharmacokinetic and safety results supporting the regimen's profile will also be presented. The EASL Congress 2025 will take place May 7-10 in Amsterdam, Netherlands....
23.04.25 - 11:30
Presentation of 1[st] quarter 2025 results (Cision)
 
Atea ASA will present its 1[st] quarter 2025 financial results on Tuesday, 29 April 2025 at 08:00 CEST. The presentation will be held at Atea, Karvesvingen 5, Oslo, Norway (meeting room on the 2[nd] floor). In addition to presenting the 1[st] quarter 2025 results, the company will provide an update on the business. The quarterly report, presentation material, and webcast will be available at: https://www.atea.com/financial-reports/ For further information, please contact: Robert Giori, CFO, Atea ASA, mobile (+47) 934 09 188   About Atea Atea is the leading supplier of IT...
17.04.25 - 14:09
Atea Pharmaceuticals announces share repurchase program (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
17.04.25 - 13:03
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program (GlobeNewswire EN)
 
Enters into Agreement with Bradley L. Radoff and Michael Torok Enters into Agreement with Bradley L. Radoff and Michael Torok...
09.04.25 - 13:03
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (GlobeNewswire EN)
 
Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect...
26.03.25 - 19:15
Atea Pharmaceuticals cuts workforce by ~25% in Q1 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
26.03.25 - 19:00
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value (GlobeNewswire EN)
 
BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today issued the following statement:...
25.03.25 - 17:00
Atea ASA - share buyback completed (Cision)
 
Oslo, 25 March Please see below information about transactions made under the share buyback programme for Atea ASA. Date on which the buyback programme was announced: 23 October 2024 The duration of the buyback programme: 23 October 2024 to 29 April 2025, or until the maximum number of shares has been repurchased. Size of the buyback programme: Up to 650,000 shares From 21 March 2025 until 25 March 2025, Atea ASA has purchased a total of 25,325 own shares at the Oslo Stock Exchange at an average price of NOK 131.47 per share. Following the completion of the above transactions,...
21.03.25 - 22:57
Atea Pharmaceuticals Issues Statement Regarding Director Nominations (GlobeNewswire EN)
 
No Shareholder Action is Required at this Time No Shareholder Action is Required at this Time...
20.03.25 - 21:00
Key information relating to cash dividend to be paid by Atea ASA (Cision)
 
The Board of Atea ASA has proposed cash dividend with two payments, and with following key details:   Dividend amount:                          3.50 per share Declared currency:                        NOK Last day including right:                20.05.2025 Ex-date:                                        21.05.2025 Record date:                                 22.05.2025 Payment date:                              27.05.2025 Date of approval:                          29.04.2025 Dividend amount:                         3.50 per share Declared currency:                       NOK...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wer das Recht mit Füßen tritt, steht selten fest auf den Beinen. - Stanislaw Jerzy Lec
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!